- Matinas Biopharma press release ( NYSE: MTNB ): Q2 GAAP EPS of -$0.03 in-line.
- Revenue of $1.06M beats by $1M .
- “The second quarter of 2022 through today has been a period of significant execution for our Company, and especially for our lead, late stage clinical asset, MAT2203,” commented Jerome D. Jabbour, Chief Executive Officer of Matinas . “Several meetings with the U.S. Food and Drug Administration (FDA) over the past few months have provided clarity around a flexible, streamlined approval pathway for this potentially game-changing drug, based on a single Phase 3 registration trial now scheduled to commence in the first quarter of 2023. We also remain very enthusiastic about our ongoing exclusive research collaboration with BioNTech and are diligently working toward what we believe will be a mutually beneficial licensing arrangement for the application of our proprietary LNC platform in the rapidly developing mRNA space. Additional validation of the capabilities of the LNC platform and developing an internal and external pipeline of LNC-based drug candidates continue to be key objectives for Matinas in the second half of 2022 and throughout 2023.”
For further details see:
Matinas Biopharma GAAP EPS of -$0.03 in-line, revenue of $1.06M beats by $1M